Opinion | A WHO Exit Is a Huge Mistake
Beyond global health, this is a threat to national security
Related Articles
AbbVie to Host Fourth Quarter 2024 Earnings Conference Call | AbbVie
The Investor Relations website contains information about AbbVie’s business for stockholders, potential investors, and financial analysts.
Genentech: Press Releases | Monday, Jan 27, 2025
Discover the latest news about our company, our products, our policies, and our people.
How Trump’s Initial Executive Orders May Impact Medicaid, Medicare Models
Adam Colborn, JD, of AMCP, discussed how President Trump’s rescission of several Biden-era executive orders may impact Medicaid and Medicare initiatives.
New York City’s Public Health Program to Provide Immunizations and Primary Care to Immigrant Children and Families
This article describes the challenges and lessons learned in conducting a major public health campaign to connect immigrant children and their parents to school-required immunizations…
Exploring Screening Central – the first telehealth-enabled platform to request T1D screening – with Mariano Bendersky
Published on: January 30, 2025 Type 1 diabetes (T1D) can happen to anyone, at any age, regardless of family history. Unfortunately, up to 40% of…
Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More – MedCity News
Astellas Pharma still looks to grow in cancer with a pipeline that includes internally developed programs that could stand out in oncology. But the drugmaker…
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023; AUSTEDO ® – exceeding $1.6 billion in revenues,…
Shorter Oral Regimens Measure Up to Standard Ones for Rifampin-Resistant TB
Randomized trial supports three, 9-month regimens with broad applicability
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis – Merck.com
Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION…
Teva Pharma CEO: Guidance based on the new Teva that grows every year
Richard Francis, Teva Pharmaceuticals CEO, joins ‘Money Movers’ to discuss the company’s quarterly earnings results, drug price negotiations, and much more.